Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'
August 11, 2014 11:05 AM EDTAegis Capital affirms Inovio Pharmaceuticals (AMEX: INO) at Buy with a target price of $19 following Q2 results and update released earlier Monday.
Analyst Ram Selvaraju commented, This morning, Inovio reported financial results for the second quarter of 2014. The firm closed the... More
Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share
August 11, 2014 9:17 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $1.8 million.
Dr. J. Joseph Kim, President and CEO, said, "Our second quarter marked a historical... More
